FDA Moves to Transform Plant Inspection System - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

FDA Moves to Transform Plant Inspection System
ORA leadership looks to staff redeployment and risk management to ensure product quality despite diminishing resources.

Pharmaceutical Technology

International adoption of risk-based inspection models and more information sharing offer prospects for relief. Although no one is looking for mutual recognition of inspection decisions by foreign agencies, there is growing interest in bilateral agreements for sharing inspection information among regulatory authorities. US membership in the Pharmaceutical Inspection Cooperation Scheme (PIC/S), which is moving forward, could expand acceptance of PIC/S certificates that a plant meets GMP standards. Foreign regulators could save resources by first examining what inspection report information is available from PIC/S, from FDA's inspections database, and from an EU database now under development. And, clarification by the World Health Organization of its recommendations for when plant inspections are needed would be helpful.

Increased reliance on risk management to reduce low-priority oversight by FDA assumes stronger self-regulation and compliance by industry. Manufacturers with sound GMP compliance histories and corporate-integrity programs may gain some regulatory relief, especially for low-risk products.

FDA aims to encourage manufacturers to ensure product quality by establishing internal quality-control units, written process-control procedures, and processes to fully validate operations. Such policies can demonstrate a corporate environment that encourages compliance with rules and regulations.

Jill Wechsler is Pharmaceutical Technology's Washington editor, 7715 Rocton Ave., Chevy Chase, MD 20815, tel. 301.656.4634,


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here